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Available online 11 March 2016Background: The up- and down-regulation of the osteoclastogenesis response depends on the estrogen/estrogen
receptor (ER) signaling pathway. Previous reports have shown that the promoter hypermethylation and gene
polymorphism of ERα are risks for menopausal osteoporosis. No previous study has evaluated the expression
levels of ERαmRNA in menopausal osteoporosis using human subjects. We hypothesized that ERαmRNA ex-
pression may show less resistance to postmenopausal osteoporosis.
Methods: In this study, we enrolled 107 women older than 45 years without menstruation and classiﬁed them
into control, osteopenia, and osteoporosis groups depending on their T-scores. The ERαmRNA levels in periph-
eral blood cells (PBCs) were analyzed via quantitative real-time reverse-transcription polymerase chain reaction
(QRT-PCR), and estrogen in the serum was detected via ELISA.
Results: ERαmRNA levels in PBCs had a negative correlationwith age and a positive correlationwith estrogen and
BAP in the osteopenia and osteoporosis groups, but not in the control group. Additionally, multivariate analysis
showed that older age (N55 years), and low ERαmRNA levels in PBLs (≦250.39 copies/μg DNA) were associated
with an approximately 9.188-, and 31.25-fold risk of osteoporosis.
Conclusion:We conclude that ERαmRNA levels in PBLs could be used as an independent risk factor for postmen-
opausal osteoporosis.
General signiﬁcance: Our ﬁndings suggested that ERαmRNA levels in PBLs may be more important than age and
serum estrogen levels.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Osteoporosis1. Introduction
Osteoporosis is a silent and progressive systemic skeletal disorder
characterized by compromised bone strength. Osteoporosis in the
aged population has become increasingly important due not only to
an increase in the number of postmenopausal women because of the
aging population worldwide but also to the fact that more women are
living longer and are, therefore, more prone to osteoporosis [1]. Osteo-
porosis may predispose these individuals to consequential increases in
fracture risk, and osteoporosis is often only diagnosed after a fracture.
Fracture risk refers to the resilience of the bone to trauma; bone
strength is, in turn, dependent on mineral quantity and bone quality.rest in any material or device
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. This is an open access article underEstrogen is essential for bone growth and for the development and
maintenance of bone health in adulthood [2,3]. The cellular responses
of osteoblasts and osteoclasts to estrogen are initiated via the high-
afﬁnity receptor. Osteoblasts synthesize the receptor activator of the
NF-κB ligand (RANKL) and the decoy receptor osteoprotegerin (OPG),
which is necessary for modulating osteoclast formation and function
[4,5]. Because the inhibition of osteoclastogenesis is one of the main
mechanisms by which estrogen (estradiol) prevents bone loss, it is like-
ly that estradiol may regulate either the production of RANKL or target
cell responsiveness to RANKL [6]. Thus, estrogenmaydown-regulate os-
teoclastogenesis via a differential decrease in the responsiveness of os-
teoclast precursors to RANKL and by directly suppressing RANKL-
induced osteoclast differentiation. The lack of estrogen decreases the
differentiation of cells of monocytic lineage into mature osteoclasts. In
2003, Bord et al. ﬁrst demonstrated estrogen-induced changes in OPG
and RANKL that were mediated by ER expression [6]. Hertrampf et al.
suggested that ERα but not ERβ agonists of estrogen exerted bone-
protective effects by modulating the activity of osteoclasts and osteo-
blasts [7]. ERs, speciﬁcally ERα, are involved in bone cells' earlythe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Clinical parameters of control, osteopenia, and osteoporosis groups in this study.
Parameters Control Osteopenia Osteoporosis p value
(n = 31) (n = 45) (n = 45)
Age (years) 55.04 ± 10.31a 60.90 ± 10.06 75.53 ± 10.41 b0.0001
Height (cm) 156.3 ± 4.56 154.31 ± 5.23 149.38 ± 6.12 b0.0001
Weight (kg) 60.95 ± 5.50 58.58 ± 10.77 54.52 ± 10.75 0.020
BMI (kg/m2) 24.98 ± 2.55 24.63 ± 4.42 24.45 ± 4.73 0.672
LBMD (g/cm2) 1.19 ± 0.13 0.93 ± 0.09 0.69 ± 0.13 b0.0001
HBMD (g/cm2) 1.01 ± 0.12 0.84 ± 0.09 0.64 ± 0.13 b0.0001
ERαmRNA 250.39 ± 550.56 50.35 ± 173.81 9.35 ± 32.77 b0.0001
E2 (pg/ml) 55.35 ± 56.01 46.86 ± 33.97 36.98 ± 11.81 0.442
T-score-lumbar 0.43 ± 0.91 −1.67 ± 0.45 −3.60 ± 0.81 b0.0001
Z-score-lumbar 0.75 ± 1.14 −0.74 ± 0.70 −1.6 ± 0.79 b0.0001
T-score-hip 0.44 ± 0.91 −1.02 ± 0.68 −2.36 ± 1.22 b0.0001
Z-score-hip 0.95 ± 0.91 0.03 ± 0.80 −0.284 ± 0.92 b0.0001
BAP 1.83 ± 1.37 2.31 ± 1.64 1.64 ± 1.05 0.383
CTX 0.27 ± 0.18 0.24 ± 0.18 0.39 ± 0.39 0.328
BMI: body mass index (kg/m2).
LBMD: lumbar bone mineral density (g/cm2).
HBMD: hip bone mineral density (g/cm2).
BAP: bone-speciﬁc alkaline phosphates.
CTX: carboxy-terminal telopeptide.
p values were analyzed by two-independent sample tests.
a Mean ± standard deviation.
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osteoblasts and osteocytes are regulated by estrogen [11]. In addition,
aromatase inhibitor use in postmenopausal breast cancer patients po-
tentially impairs their bone quality, implying that the interaction be-
tween ERα and even tiny amounts of serum E2 in postmenopausal
women is a valid signaling system in bone health [12–14]. Therefore,
the down-regulation of ERα associated with low levels of estrogen
may reduce the effectiveness of bone cells' ERα-mediated responses
to strain [15,16].
The up- and down-regulation of the osteoclastogenesis response de-
pends on three mechanisms: the number of estrogen receptors, the
binding of the estrogen in an effective manner, and the transduction
of the signal in the cell [10,15]. If any of these three components is
ﬂawed, estrogen binding to the receptor may not prevent bone loss.
Therefore, we postulated that the expression of ERα mRNA in PBCs
may serve as a barometer of gene activity of monocytic cell lineage in
osteoclasts.
Therefore, we investigated whether (1) the expression levels of ERα
mRNA in PBCswere different between the control, osteopenia, and oste-
oporosis groups of menopausal women, (2) the ERαmRNA expression
levels were correlated with clinical markers of osteoporosis, and
(3) ERαmRNA expression levels could be used as an independent bio-
marker for osteoporosis.
2. Materials and methods
2.1. Subjects
In a cross-sectional study conducted from 2010 to 2012, we enrolled
107 women older than 45 years without menstruation and classiﬁed
them into control, osteopenia, and osteoporosis groups depend on
their T-scores. The deﬁnition of osteoporosis was based on the catego-
ries created by theWorld Health Organization (WHO) for bone density
in white women. The WHO deﬁnition of osteopenia is a T-score below
−1.0 and above−2.5; for osteoporosis, it is a T-score less than−2.5.
We excluded patients whowere bedridden, using steroids, on hormone
therapy, or dependent on alcohol or who had a history of renal disease
or cancer. The patients enrolled in this study being diagnosedwith oste-
oporosis for the ﬁrst time. The blood sampleswere collected before clin-
ical treatment. All patients were subgroups of experimental and control
groups based on our previous report in 2010 [17]. We determined and
recorded demographic data (age, height, weight, BMI) and clinical
data (bone mineral density [BMD], ERα and estrogen levels, bone-
speciﬁc alkaline phosphates [BAP], carboxy-terminal telopeptide
[CTX], T- and Z-scores) for the three groups at the time of diagnosis
(Table 1). The deﬁnition of high and low expression of estrogen, ERα
mRNA and clinical parameters were dependent on the mean value of
the control group. Values higher than the mean were deﬁned as high.
Expression levels lower than the mean were deﬁned as low.
The BMD for all candidates was determined via dual-energy X-ray
absorptiometry of the lumbar spine, femoral neck, and Ward's triangle.
All participants submitted written informed consent, and the studywas
approved by institutional review board of Chung Shan Medical Univer-
sity Hospital. This was a pilot study. Based on our sample size, the value
of the power analysis of this case–control study was N0.9.
2.2. ELISA of estrogen levels
The levels of estrogen in the serum were calculated using the
enzyme-linked immunosorbent assay (ELISA) method with
TiterZyme® estrogen-detection ELISA kits (DRG International, Inc.,
Mountainside, NJ, USA). The plates were incubated with phosphate-
buffered saline (PBS)-Tween® containing 1% fetal calf serum (Gibco,
Carlsbad, CA, USA) at 37 °C for 60 min to block nonspeciﬁc binding. Es-
trogen standards and serum samples were added to the plate. After in-
cubation at 37 °C for 60 min, 100 μL of yellow antibody was added, butnot to the blank, and the plates were incubated at room temperature for
60min. After a PBSwash, 100 μL of blue conjugatewas added, but not to
the blank, and the plates were incubated at room temperature for
30 min. The plates were washed, and the substrate solution and color
were added and measured at 570 and 590 nm via a microtiter plate
reader (Model 550; BIO-RAD, Hercules, CA, USA). The concentration of
estrogen was calculated using linear graph paper, plotting the average
net optical density for each standard versus the human estrogen con-
centration in each standard. An approximation of a straight line was
drawn through the points. The concentration of human estrogen in
the serum was determined via interpolation.2.3. QRT-PCR for ERαmRNA expression
The ERαmRNA expression in the PBCs was detected via QRT-PCR.
The total RNA was isolated from the PBCs. Cells were isolated using
1 mL Trizol® reagent (Invitrogen, Carlsbad, CA, USA), followed by chlo-
roform re-extraction and isopropanol precipitation. Three micrograms
of total RNA from lung cancer cells were reverse transcribed using
Moloney murine leukemia virus reverse transcriptase (M-MLV;
Promega, Madison, WI, USA) and oligo d(T)15 primer. QRT-PCR was
performed in a ﬁnal volume of 25 μL, containing 1 μL cDNA template,
0.2 μMprimer, and 12.5 μL SYBR® greenmaster mix (Molecular Probes,
Inc., Eugene, OR, USA). The primers were designed using the ABI Primer
Express 3.0 Software (Applied Biosystems, Foster City, CA, USA). The se-
quences of the primers used were 5′-TGATTGGTCTCGTCTGGCG-3′ and
5′-CATGCCCTCTACACATTTTC-CC-3′ for ERα and 5′-GACTCTTTCGAGGC
CCTGTAATT-3′ and 5′-TCCCAAGATCCAACTACGAGC-T-3′ for the 18S
gene. Quantiﬁcation was carried out using the comparative CT method,
and water was used as the negative control. An arbitrary threshold was
chosen on the basis of the variability of the baseline. Threshold cycle
(CT) values were calculated by determining the point at which the ﬂuo-
rescence exceeded the threshold limit. CT was reported as the cycle
number at this point. The average of the target gene was normalized
to 18S rRNA as an endogenous housekeeping gene. After cycling, the rel-
ative quantiﬁcation of ERαmRNA against an internal control, 18S, was
conducted via the ΔCT method [18]. The deﬁnition of high and low ex-
pression of ERαmRNA was dependent on the mean value of gene ex-
pression in the control group. Expression levels higher than the mean
were deﬁned as high. Expression levels lower than the mean were de-
ﬁned as low.
Table 2
Correlation of ERα mRNA expression and clinical parameters of control and disease
groups.
ERαmRNA All Control group Disease group
(n = 107) (n = 31) (n = 76)
p r p r p r
Age 0.003 −0.285 0.377 −0.174 0.022 −0.263
E2 0.283 0.010 0.352 0.194 0.001 0.458
Height 0.244 0.115 0.565 −0.114 0.261 0.130
Weight 0.890 −0.014 0.146 −0.282 0.642 −0.054
BMI 0.503 −0.066 0.347 −0.185 0.342 −0.110
T-score (L) 0.001 0.335 0.419 0.159 0.118 0.181
Z-score (L) 0.001 0.331 0.290 0.207 0.479 0.082
T-score (H) 0.004 0.323 0.399 0.185 0.328 0.137
Z-score (H) 0.021 0.264 0.361 0.200 0.937 −0.011
CTX 0.414 −0.080 0.557 −0.116 0.638 −0.055
BAP 0.738 0.033 0.578 −0.110 b0.0001 0.411
L: lumbar.
H: hip.
BAP: bone-speciﬁc alkaline phosphates.
CTX: carboxy-terminal telopeptide.
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In this study, the datawere presented asmean± SD.We determined
the differences in ERαmRNA between the control and disease groups
using aMann–Whitney test. The correlations betweenERαmRNA, estro-
gen, age, T-scores, and Z-scores were calculated using the Pearson corre-
lation method for all subjects. To determine whether ERαmRNA could
be used as an independent risk factor for osteoporosis, a multiple uncon-
ditional logistic model was used to obtain the adjusted odds ratios (ORs)
for the difference in ERαmRNAand estrogen status, and a corresponding
95% CI was used for the T-score after adjusting for the effect of potential
confounding factors. The factors used in the multivariate were analyzed
via univariate analysis ﬁrst; if the p value was less than 0.05, they were
subjected to multivariate analysis. In order to determine the change in
the age, body height, body weight, serum estrogen levels, and ERα
mRNA in PBCs, the area under the curve per year (AUC/year) was calcu-
lated. All the statistical analyses were performed using SAS® 9.1 statisti-
cal software (SAS Institute, Inc., Cary, NC, USA). All p values were
calculated from two-tailed statistical tests.
3. Results
3.1. Clinical data for control, osteopenia, and osteoporosis groups at the
time of diagnosis
We enrolled 107 women older than 45 years without menstruation,
and the study subjects were stratiﬁed into three groups (31 control, 31
osteopenia, and 45 osteoporosis groups) depending on their T-score. As
showed in Table 1, the age (p b 0.0001), body height (p b 0.0001), bodyFig. 1. PBL ERα mRNA (A) and estrogen (B) levels in the control, osteopenia, and
osteoporosis groups.weight (p=0.020), LBMD (p b 0.0001), HBMD (p b 0.0001), ERαmRNA
(p b 0.0001), lumbar and hip T-score (p b 0.0001), and lumbar and hip
Z-score (p b 0.0001) of these three groups were signiﬁcantly different.
No signiﬁcant differences were found for BMI, serum estrogen levels
BAP, and CTX (p = 0.672 for BMI; p = 0.442 for E2; p = 0.383 for
BAP; p= 0.328 for CTX).
3.2. ERαmRNA in PBCs and serum estrogen levels in the control, osteopenia,
and osteoporosis groups
To determine whether the ERαmRNA in the PBCs and in serum es-
trogen levels was different between the control, osteopenia, and osteo-
porosis groups of menopausal women, the expression levels of ERα
mRNA in the PBCs were detected via real-time RT-PCR. As shown in
Fig. 1, the expression levels of ERαmRNA in the PBCs of themenopausal
control groupwere signiﬁcantly higher than in the osteopenia and oste-
oporosis groups (PBCs ERα mRNA: 250.39 ± 550.56 for the control
group, 50.35 ± 173.81 for the osteopenia group, and 9.54 ± 32.77 for
the osteoporosis group, p b 0.0001, Fig. 1A). No signiﬁcant differences
in the Estrogen levels in the serum were found between the control,
osteopenia, and osteoporosis groups (serum Estrogen: 55.35 ± 56.01
for the control group, 46.86 ± 33.97 for the osteopenia group, and
36.98 ± 11.81 for the osteoporosis group, p= 0.442, Fig. 1B). The data
demonstrate that ERα mRNA in PBCs plays a role in osteoporosis
progression.
3.3. ERαmRNA in PBCs was correlated with age, serum estrogen levels, and
BAP in the disease groups, but not in the control group
To further verify whether the role of ERαmRNA in the PBCs in the
control and disease groups (the osteopenia and osteoporosis groups)
was different, the correlations between ERα mRNA levels in the PBCsTable 3
Logistic regression analysis of various potential risk factors in osteoporosis of menopausal
group.
Variable Unfavorable/favorable OR 95% CI p value
Age b55/≧55 9.188 2.211–38.177 0.002
ERαmRNA b250.39/≧250.39 31.25 1.357–1000 0.032
(Copies/μg DNA)
Body height (cm) b156.3/≧156.3 3.472 0.792–15.15 0.099
Body weight (kg) b60.95/≧60.95 1.153 0.264–5.025 0.849
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the disease groups were analyzed. As shown in Table 2, in the disease
group, ERα mRNA had a negative correlation with age (r = −0.263,
p= 0.002) and a positive correlation with serum estrogen levels (r =
0.458, p=0.001) and BAP (r=0.411, p b 0.0001). There was no corre-
lation with the other factors, including body height (r = 0.130, p =
0.261), body weight (r =−0.054, p = 0.642), T-score in the lumbarFig. 2. Changes in (A) age, (B) body height, (C) body weight, (D) serum E2 levels, and (E) ERα
operating characteristic (ROC) curve.area (r = 0.181, p = 0.118), T-score in the hip area (r = 0.137, p =
0.328), BMI (r = −0.110, p = 0.342), lumbar Z-score (r = 0.082,
p = 0.479), hip Z-score (r = −0.011, p = 0.937), and CTX
(r=−0.055, p=0.638). The results for the disease groupswere differ-
ent than in the control group. In the control group, the ERαmRNA levels
in the PBCs were not correlated with any clinical parameters, including
age (r =−0.174, p = 0.377), serum estrogen levels (r = 0.197, p =mRNA in PBCs in osteoporosis progression. The results were analyzed using the receiver
128 C.-W. Chou et al. / BBA Clinical 5 (2016) 124–1290.352), body height (r = −0.114, p = 0.565), body weight
(r =−0.282, p = 0.146), T-score in the lumbar area (r = 0.159, p =
0.419), T-score in the hip area (r = 0.185, p = 0.399), BMI
(r =−0.185, p = 0.347), lumbar Z-score (r = 0.207, p = 0.290), hip
Z-score (r = 0.361, p = 0.264), CTX (r = −0.116, p = 0.557), and
BAP (r =−0.110, p= 0.578).
3.4. Low ERα mRNA levels in PBLs correlate with age as independent risk
factors for menopausal osteoporosis
To elucidate which variable increased the risk of osteoporosis in
menopausalwomen,multivariate logistic regression analyseswere per-
formed. The age, body height, body weight and ERαmRNA levels were
adjusted. Our data showed that older persons (N55 years old), and those
with low ERαmRNA levels in PBCs (≦250.39 copies/μg DNA) had an ap-
proximately 9.188-, and 31.250-fold risk of osteoporosis as compared
with healthy persons (≦55 years old; 95% CI = 2.211–38.177, p =
0.002), and those with high ERα mRNA levels in PBLs (N250.39 cop-
ies/μg DNA; 95% CI = 1.357–1000, p = 0.032) (Table 3). Thus, ERα
mRNA levels in PBLs are correlatedwith age as independent risk factors
for menopausal osteoporosis.
3.5. Expression of ERαmRNA could be used as a biomarker of osteoporosis
To further conﬁrm whether the changes in the expression levels of
ERαmRNAs could be used as a useful biomarker in osteoporosis, we an-
alyzed the receiver operating characteristic (ROC) curve. As shown in
Fig. 2, age (AUC = 0.761, p b 0.0001), body height (AUC = 0.729, p=
0.001), body weight (AUC = 0.669, p = 0.017), and ERα mRNA
(AUC = 0.768, p b 0.0001) have good predictability, but not serum es-
trogen (AUC = 0.554, p = 0.460). Thus, the expression levels of ERα
mRNA in the PBCs of osteoporosis patients acted as a signiﬁcant risk bio-
marker for the development of osteoporosis.
4. Discussion
The decline in estrogen function is themain cause ofmenopausal os-
teoporosis. The action of estrogen is mediated by its binding to ERα and
entry into the cell to activate the ERα-related signaling pathway. In this
study, we found that the levels of ERαmRNA in PBCs are more impor-
tant than estrogen in increasing the risk of osteoporosis and that they
are promising markers for the early diagnosis of postmenopausal
osteoporosis.
It is well-known that cells of monocytic lineage differentiate into os-
teoclasts [8–11]. In addition, changes in ERmRNA in the osteoblast have
been reported in disease processes [8–11]. In present study, we found
that the expression levels of ERαmRNA in the PBLs of the menopausal
control groupwere signiﬁcantly higher than in the osteopenia and oste-
oporosis groups (Fig. 1A). In addition, the analysis results of ROC curve
showed that ERαmRNA (AUC = 0.768, p b 0.0001) have good predict-
ability (Table 3). Thus, the expression levels of ERαmRNA in the PBCs of
osteoporosis patients acted as a signiﬁcant risk biomarker for the devel-
opment of osteoporosis. However, the detection of these biomarkers
using the osteoblasts of osteoporosis patients is difﬁcult to apply in
the clinic in order to monitor the disease. The detection of ER mRNA in
the peripheral blood, either cell-associated or cell-free, holds great poten-
tial for the non-invasive and real-timemolecular monitoring of diagnosis
and treatment effects for this disease. In this study, the expression levels
of ERα mRNA in PBCs were detected via real-time RT-PCR. Diagnostic
quantitative PCR is applied to rapidly detect nucleic acids that are diag-
nostic of several types of disease. This assay is high-throughput and
rapid. In clinical settings, examining ERαmRNA levels is easy. In addition,
an ideal biomarker of a disease is released into the systemic circulation or
another body ﬂuid, where it can be detected in a blood-based assay or an
assay of another accessible body ﬂuid. Thus, we believe that theexpression levels of ERαmRNA in PBCs can be used as an important bio-
marker for osteoporosis progression and therapy.
Lv et al. (2011) showed that the frequency of promoter hypermethy-
lation of ERα in postmenopausal women was signiﬁcantly higher than
in menopausal women [19]. In addition, several reports showed that
the genetic polymorphism of ERα is a risk factor for osteoporosis in
postmenopausal women [20,21]. Both promoter hypermethylation
and genetic polymorphism reduce ERαmRNA transcription. No previ-
ous studyhas focused on the expression levels of ERαmRNA in osteopo-
rosis using human subjects. Our data frommenopausal women indicate
that the expression of ERα mRNA is decreased in PBLs from patients
with osteoporosis as compared with patients without osteoporosis.
The decreased ERα mRNA expression in PBCs in patients with meno-
pausal osteoporosis could reﬂect either a predisposing factor or a conse-
quence of the disease. Our data also showed that menopausal women
with low ERαmRNA expression in PBLs (≦250.39 copies/μg) had an ap-
proximately 31.250-fold risk of osteoporosis as compared with women
with high ERα expression (N250.39 copies/μg). ERαmRNA expression
in PBCs could be used as a biomarker and indicate that estrogen has
therapeutic beneﬁts in menopausal women.
Selective estrogen receptor modulators (SERMs) are a class of com-
pounds that interactwith intracellular ERs in target organs as estrogen ag-
onists and antagonists [22]. They include chemically diverse molecules
that lack the steroid structure of estrogens but possess a tertiary structure
that allows them to bind to ERα and/or ERβ [23]. In this study, we dem-
onstrated that ERαmRNA levels in PBCs were an important risk factor
for osteoporosis. Therefore, we suggested that ERαmRNA levels in PBCs
may use to predict the therapeutic response of SERMs.
5. Conclusion
In conclusion, our ﬁndings support the view that both estrogen and
ERαmRNA levels play a role in human postmenopausal osteoporosis.
Abundance of residual ERα mRNA leading to effective utilization of
serum E2 might be important in slowing osteoporosis progression.
New approaches to the development of anti-bone-resorptive medicine,
particularly those designed to increase the expression of ERα, should be
studied further. Genetic analyses of ERα gene polymorphismsmay pre-
dict which patients are at a higher or lower risk of postmenopausal os-
teoporosis. The evaluation of ERαmRNA expression in PBCs could help
to improve the assessment of fracture risk.
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